Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01474993 · ClinicalTrials.gov registry record · Phase 2
Sulforaphane-rich Broccoli Sprout Extract for Autism
A Phase 2 study of Autism, sponsored by Andrew Zimmerman.
- Completed
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
- 1
- Study location
NCT01474993: Completed Phase 2 study of Autism, sponsored by Andrew Zimmerman.
NCT01474993 is a Phase 2 study of Autism that has completed, run by Andrew Zimmerman. The registered enrollment target is 44 participants, below the 183-participant average among 104 other Autism trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01474993, a Phase 2 study of Autism, has completed, sponsored by Andrew Zimmerman.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objectives of this study are to answer whether there is evidence of measurable effects on social responsiveness (primary outcome) and other behavioral symptoms after treatment of autistic male adolescents and adults with orally administered sulforaphane-rich Broccoli Sprout Extract (efficacy). The secondary objectives of this study are to answer whether treatment of male adolescents and adults with autism using orally administered sulforaphane-rich Broccoli Sprout Extract within a specified dose range is safe (toxicity); treatment with sulforaphane-rich Broccoli Sprout Extract is well tolerated (side effects and adverse events); key cellular biomarkers support the hypothesized mechanisms (proof of principle).
Primary Outcome
The Social Responsiveness Scale is a parent- and/or teacher-reported 65 question scale. Each question on the scale inquires about an observed aspect of reciprocal social behavior that is rated on the scoring sheet on a scale from "0" to "3", where 0 is best possible behavior and 3 is the worst possible behavior. The total SRS score may range from 0 to 195 where higher values represent the worse outcome. For the purposes of this study, SRS scores were obtained at both screening (the day study pa
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Sulforaphane-rich Broccoli Sprout Extract
Study Locations (1)
Massachusetts
- Lurie Center for Autism, MassGeneral Hospital for Children - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2011-12 |
| Est. Completion | 2013-11 |
| Phase | Phase 2 |
What the finished NCT01474993 record still lists
NCT01474993 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 183-participant average among 104 other Autism trials with a reported enrollment target (76% lower).
The record links to 1 condition, with Autism appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01474993 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01474993 about?
NCT01474993 is a clinical study titled "Sulforaphane-rich Broccoli Sprout Extract for Autism". The primary objectives of this study are to answer whether there is evidence of measurable effects on social responsiveness (primary outcome) and other behavioral symptoms after treatment of autistic male adolescents and adults with orally administered sulforaphane-rich Broccoli Sprout Extract (effi...
What is the current status of trial NCT01474993?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2011-12. Estimated completion is 2013-11.
What conditions does trial NCT01474993 study?
This clinical trial studies the following conditions: Autism.
What interventions are being tested in trial NCT01474993?
The interventions under investigation include: Placebo (DRUG), Sulforaphane-rich Broccoli Sprout Extract (DRUG).
Who is sponsoring clinical trial NCT01474993?
This trial is sponsored by Andrew Zimmerman, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01474993 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01474993's enrollment target sits among peer trials
44 60th of 104 higher than 41 of 104 other Autism trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Autism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Optimizing Outcomes for Young Autistic Children
RECRUITING · Phase 2
-
The Impact of a Virtual Magic Trick Training Program
RECRUITING · Phase 2
-
Trial of Zolpidem for Sleep in Children With Autism
RECRUITING · Phase 2
-
A Study of Esomeprazole in Children With Autism
RECRUITING · Phase 2
-
Trial of Diphenhydramine for Sleep in Children With Autism
RECRUITING · Phase 2
-
Trial of Suvorexant for Sleep in Children With Autism
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia